X
ESMO 2017 round up: BMS and AZ bounce back
https://pharmaphorum.com/news/esmo-2017-round-bms-az-bounce-back/
ESMO17
Rubraca outshines rivals in ovarian cancer maintenance therapy
Clovis’ Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
ESMO 2017 preview: AstraZeneca‘s comeback, IO shifts to earlier use
A look ahead at some of the most eye-catching data and trends at ESMO 2017
Roche’s Alecensa shows big benefit in brain mets, advanced lung cancer
Roche’s Alecensa has shown strong results in two studies looking at its benefits in ALK positive non-small cell lung cancer (NSCLC) patients, both in first line use and a second line setting.
